Ro 5-3335

inhibits gene expression by HIV-1 at the level of transcriptional trans-activation by Tat

Also Known As:

7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2(H)-one; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

1.	Shock 10/14/2016 - "Importantly, treatment with the RUNX1 inhibitor, Ro 5-3335, protected mice from LPS-induced endotoxic shock and substantially reduced the IL-6 levels. "
2.	Infections 11/30/1992 - "Ro 5-3335, a novel antagonist of human immunodeficiency virus type 1 (HIV-1) Tat activity, inhibits acute and chronic HIV-1 infection in T lymphocytes. " 11/30/1992 - "Here we describe the effects of Ro 5-3335 on the accumulation of viral DNA during primary infection, the induction of virus from a latently infected cell line, and the expression of virus upon activation of naturally infected T cells. " 11/30/1992 - "Ro 5-3335 permitted initial DNA synthesis during primary infection, but inhibited the subsequent increase in viral DNA copy number. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 03/01/1993 - "In addition, in antagonizing extracellular TAT's actions, Ro 5-3335 could alleviate the syndrome commonly associated with AIDS as Kaposi's syndrome. " 03/01/1993 - "Theoretically, Ro 5-3335 and now its analogue Ro 24-7429 seem to possess all virtues to antagonize evolutive and latent AIDS. " 03/01/1993 - "Ro 5-3335 is a new benzodiazepine highly active in vitro (IC50 = 0.1-1.0 microM [corrected]) against HIV-1 viruses of AIDS resistant or non-resistant to zidovudine (AZT). "
4.	Squamous Cell Carcinoma of Head and Neck 01/01/2023 - "Runx1 inhibitor Ro 5-3335 can effectively inhibit KRAS-mutated HNSCC progression both in vitro and in vivo. "